Skip to content
TrialMatch
Sign up
Recruiting

High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)

Create a profile to match View the full record on ClinicalTrials.gov

About this study

The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau. Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, together with their donors, are systematically enrolled. The registry collects demographic, diagnostic, treatment, prognosis, and medical expense information, as well as biospecimens for future analyses. Historical data are incorporated, and prospective data collection is ongoing with long-term follow-up planned. The registry is designed as a sustainable research infrastructure to provide comprehensive data on disease incidence, treatment patterns, outcomes, and resource utilization in a high-altitude setting.

Condition
Hematopoietic Stem Cell Transplantation (HSCT), Acute Myeloid Leukemia (AML), Leukemias, Acute Myeloid, Myeloid Leukemias, Acute, Hemophilia, Myelodysplastic Syndrome, MDS, Lymphoma, Leukemia, Aplastic Anemia, Bleeding Disorders, Bone Marrow Transplantation, Multiple Myeloma, Myeloma, Multiple, Immune Reconstitution
Sponsor
Yigeng Cao,MD,PhD

Who can join

Age
Not specified
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 4

  • Study condition: Hematopoietic Stem Cell Transplantation (HSCT), Acute Myeloid Leukemia (AML), Leukemias, Acute Myeloid, Myeloid Leukemias, Acute, Hemophilia, Myelodysplastic Syndrome, MDS, Lymphoma, Leukemia, Aplastic Anemia, Bleeding Disorders, Bone Marrow Transplantation, Multiple Myeloma, Myeloma, Multiple, Immune Reconstitution
  • Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023.
  • Planned or actual hematopoietic stem cell transplantation (HSCT).
  • Provision of signed informed consent.

Exclusion 3

  • Inability to provide long-term follow-up data due to severe comorbidities or logistical reasons.
  • Substance abuse compromising adherence.
  • Any condition judged by investigators to jeopardize safety or compliance.

Where

1 site, 1 recruiting

Affiliated Hospital of Qinghai University

Xining, Qinghai, China

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.